Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 185.13% from the company’s previous close.
Other analysts also recently issued research reports about the stock. Jefferies Financial Group reissued a “buy” rating and set a $17.00 price objective (up previously from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Friday. Wedbush reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Inozyme Pharma in a research note on Monday, September 30th. Finally, Stifel Nicolaus started coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $16.14.
Get Our Latest Stock Report on INZY
Inozyme Pharma Stock Performance
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). On average, equities analysts forecast that Inozyme Pharma will post -1.68 EPS for the current year.
Institutional Investors Weigh In On Inozyme Pharma
A number of large investors have recently bought and sold shares of INZY. Vanguard Group Inc. lifted its position in shares of Inozyme Pharma by 1.4% in the first quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock valued at $18,530,000 after acquiring an additional 33,998 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in Inozyme Pharma by 40.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock valued at $20,242,000 after purchasing an additional 756,717 shares during the last quarter. Kennedy Capital Management LLC lifted its holdings in Inozyme Pharma by 52.2% in the 1st quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock valued at $3,352,000 after purchasing an additional 150,120 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Inozyme Pharma during the 2nd quarter worth about $76,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Inozyme Pharma by 16.1% during the second quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock worth $851,000 after buying an additional 26,464 shares in the last quarter. Institutional investors and hedge funds own 88.30% of the company’s stock.
Inozyme Pharma Company Profile
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Featured Articles
- Five stocks we like better than Inozyme Pharma
- How to Calculate Options Profits
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What does consumer price index measure?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
- How to Plot Fibonacci Price Inflection Levels
- The Downtrend in UPS Stock Isn’t Over Yet
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.